AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23273285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of one low- and one high-threshold test
Number of subjects: 33
Study 20104222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg per day in 6-week cycles (4 weeks on, 2 weeks off treatment)
Number of subjects: 750
Study 17674351 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 63
Study 17674351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17674351 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 63
Study 16128597 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestilan (four tablets administered in divided doses with three glasses of water before dinner and bedtime for 12 weeks)
Number of subjects: 40
Study 16128597 — intervention group
Group type: COMPARATOR
Intervention: Control (three glasses of water before dinner and bedtime for 12 weeks)
Number of subjects: 40
Study 11802259 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a mother in a supportive family
Number of subjects: 522
Study 10649921 — intervention group
Group type: EXPERIMENTAL
Intervention: LB2 Primer applied for 30 seconds
Number of subjects: 24
Study 10649921 — intervention group
Group type: EXPERIMENTAL
Intervention: 34% phosphoric acid etching for 15 seconds
Number of subjects: 24
Study 10649921 — intervention group
Group type: COMPARATOR
Intervention: Untreated dentin smear layer
Number of subjects: 24
Study 8590742 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty as a reperfusion approach
Number of subjects: 0
Study 8590742 — intervention group
Group type: COMPARATOR
Intervention: Rescue angioplasty after failed thrombolysis
Number of subjects: 0
Study 8590742 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 2073487 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (fast injection, mean 0.54 ml/second)
Number of subjects: 40
Study 2073487 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (slow injection, 0.05 ml/second)
Number of subjects: 40
Study 6986746 — intervention group
Group type: EXPERIMENTAL
Intervention: External pressure circulatory assistance for 4 or more hours within the first 24 hours after admission
Number of subjects: 258
Study 6986746 — intervention group
Group type: EXPERIMENTAL
Intervention: External pressure circulatory assistance for 3 or more hours
Number of subjects: 258
Study 6986746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group of patients with 3 or more and 4 or more hours of treatment
Number of subjects: 258
Study 29800114 — intervention group
Group type: EXPERIMENTAL
Intervention: High qSOFA score (2)
Number of subjects: 6569
Study 29800114 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate qSOFA score (1)
Number of subjects: 6569
Study 29800114 — intervention group
Group type: EXPERIMENTAL
Intervention: High SIRS criteria (2)
Number of subjects: 6569
Study 29800114 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 6569
Study 26995688 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G side-port needle
Number of subjects: 160
Study 26995688 — intervention group
Group type: COMPARATOR
Intervention: 22G standard needle
Number of subjects: 160
Study 24502951 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat milk formula
Number of subjects: 200
Study 24502951 — intervention group
Group type: COMPARATOR
Intervention: Cow milk formula
Number of subjects: 200
Study 22878073 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leaders conducted organ donation discussions and showed a tailored DVD for African American churches.
Number of subjects: 22
Study 17239068 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention started when non-blanchable erythema appeared (experimental group, n = 826)
Number of subjects: 1617
Study 17239068 — intervention group
Group type: COMPARATOR
Intervention: Standard risk assessment method (control group, n = 791)
Number of subjects: 1617
Study 15861942 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional course
Number of subjects: 160
Study 15861942 — intervention group
Group type: COMPARATOR
Intervention: Integrated course
Number of subjects: 160
Study 12019281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild bicycle exercise (30 minutes)
Number of subjects: 20
Study 12019281 — intervention group
Group type: COMPARATOR
Intervention: Control evaluation (CTRL)
Number of subjects: 20
Study 12019281 — intervention group
Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Number of subjects: 20
Study 12019281 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTEX (after exercise)
Number of subjects: 20
Study 12019281 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTEX+LBNP (after exercise and LBNP)
Number of subjects: 20
Study 12019281 — intervention group
Group type: COMPARATOR
Intervention: LBNP
Number of subjects: 20
Study 12019281 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTEX
Number of subjects: 20
Study 12019281 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTEX+LBNP
Number of subjects: 20
Study 12019281 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study 9498653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol supplementation of 800 mg/day
Number of subjects: 10
Study 9498653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8541279 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA‐EE (18 g/d for 7 days)
Number of subjects: 10
Study 2172288 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 34
Study 2172288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 81927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitisation with Dermatophagoides pteronyssinus tyrosine absorbate
Number of subjects: 0
Study 81927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31358408 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose vaccination (2D) on days 0 and 28
Number of subjects: 107
Study 31358408 — intervention group
Group type: COMPARATOR
Intervention: 3-dose vaccination (3D) on days 0, 7, and 28
Number of subjects: 107
Study 31358408 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose vaccination (2D) post-booster
Number of subjects: 107
Study 31358408 — intervention group
Group type: COMPARATOR
Intervention: 3-dose vaccination (3D) post-booster
Number of subjects: 107
Study 31358408 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose vaccination (2D) at 7-day post-booster
Number of subjects: 107
Study 31358408 — intervention group
Group type: COMPARATOR
Intervention: 3-dose vaccination (3D) at 7-day post-booster
Number of subjects: 107
Study 27916620 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/Formoterol Metered Dose Inhaler (GFF MDI) 18/9.6 μg
Number of subjects: 3718
Study 27916620 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Metered Dose Inhaler (GP MDI) 18 μg
Number of subjects: 3718
Study 27916620 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol Metered Dose Inhaler (FF MDI) 9.6 μg
Number of subjects: 3718
Study 27916620 — intervention group
Group type: COMPARATOR
Intervention: Placebo Metered Dose Inhaler (MDI)
Number of subjects: 3718
Study 26626341 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based Direct Observation of Treatment (CBDOT)
Number of subjects: 150
Study 26626341 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based Direct Observation of Treatment (HBDOT)
Number of subjects: 150
Study 22872005 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 μg/kg/day for 3 consecutive days with an additional half-dose 4 hours before surgery)
Number of subjects: 24
Study 22872005 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 24
Study 22872005 — intervention group
Group type: COMPARATOR
Intervention: Control (no G-CSF)
Number of subjects: 24
Study 21455076 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapatellar nerve block (IPNB; 10 ml levobupivacaine 0.5%)
Number of subjects: 64
Study 21455076 — intervention group
Group type: COMPARATOR
Intervention: Sham block with isotonic saline
Number of subjects: 64
Study 18095747 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 54
Study 18095747 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 45 mg
Number of subjects: 54
Study 18095747 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg
Number of subjects: 54
Study 18095747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16557381 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative interferon alpha (5 micro i.m. tiw for 18 months)
Number of subjects: 236
Study 16557381 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study 12673604 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 0
Study 12673604 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 0
Study 12673604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 12673604 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day (prior exposure)
Number of subjects: 0
Study 12673604 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day (prior exposure)
Number of subjects: 0
Study 11912812 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly follow-up
Number of subjects: 30
Study 11912812 — intervention group
Group type: COMPARATOR
Intervention: 3-month follow-up
Number of subjects: 30
Study 8866392 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation plus IUI (36 patients)
Number of subjects: 68
Study 8866392 — intervention group
Group type: COMPARATOR
Intervention: Superovulation alone (32 patients)
Number of subjects: 68
Study 1512807 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment strategies for substance abuse; specific dosages and durations not available.
Number of subjects: 0
Study 1512807 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching clients to alternative treatment strategies; specific strategies not detailed.
Number of subjects: 0
Study 1512807 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment approaches; specific details not available.
Number of subjects: 0
Study 6747752 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (0.5 ml) DTP vaccine
Number of subjects: 80
Study 6747752 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dose (0.25 ml) DTP vaccine
Number of subjects: 80
Study 31748288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored brief behavioural sleep intervention
Number of subjects: 234
Study 31748288 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 234
Study 30045425 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack containing green leafy vegetables, fruit, and milk (mean 54.1 mg ALA)
Number of subjects: 222
Study 30045425 — intervention group
Group type: COMPARATOR
Intervention: Control snack containing low micronutrient foods (mean 4.1 mg ALA)
Number of subjects: 222
Study 27487142 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 265
Study 27487142 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 265
Study 27487142 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan
Number of subjects: 265
Study 27487142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine plus bevacizumab
Number of subjects: 265
Study 27487142 — intervention group
Group type: COMPARATOR
Intervention: Lomustine
Number of subjects: 265
Study 26008757 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing a modified Sensory Motor Rhythm
Number of subjects: 30
Study 26008757 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Upper Alpha
Number of subjects: 30
Study 26008757 — intervention group
Group type: COMPARATOR
Intervention: Sham/control group (random reward)
Number of subjects: 30
Study 24041259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention from GP to parents highlighting the importance of maintaining asthma medication
Number of subjects: 14000
Study 24041259 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 14000
Study 20828635 — intervention group
Group type: EXPERIMENTAL
Intervention: GERA (genetic and environmental risk assessment) group
Number of subjects: 562
Study 20828635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 562
Study 18285374 — intervention group
Group type: EXPERIMENTAL
Intervention: SpO2 monitoring
Number of subjects: 19
Study 18285374 — intervention group
Group type: COMPARATOR
Intervention: TcPO2 monitoring
Number of subjects: 19
Study 16410446 — intervention group
Group type: EXPERIMENTAL
Intervention: ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone)
Number of subjects: 485
Study 16410446 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 485
Study 16410446 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 485
Study 16410446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ld-CHOP (low-dose CHOP)
Number of subjects: 485
Study 16410446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ld-CHOP
Number of subjects: 485
Study 16410446 — intervention group
Group type: COMPARATOR
Intervention: VS (vincristine and steroid)
Number of subjects: 485
Study 14643838 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg bid)
Number of subjects: 10
Study 14643838 — intervention group
Group type: COMPARATOR
Intervention: Amantadine (0 mg bid)
Number of subjects: 10
Study 14643838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12, 25, and 50 mg)
Number of subjects: 10
Study 10862807 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily buprenorphine (16 mg/70 kg)
Number of subjects: 92
Study 10862807 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly buprenorphine (34 mg/70 kg on Fridays and Sundays, 44 mg/70 kg on Tuesdays)
Number of subjects: 92
Study 9197932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing immune IgY (derived from egg yolks from immunized hens)
Number of subjects: 0
Study 9197932 — intervention group
Group type: COMPARATOR
Intervention: Control IgY
Number of subjects: 0
Study 9197932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing immune IgY (10% sucrose)
Number of subjects: 0
Study 9197932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing immune IgY (without sucrose)
Number of subjects: 0
Study 9197932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing immune IgY
Number of subjects: 0
Study 8156957 — intervention group
Group type: EXPERIMENTAL
Intervention: FVS (Aerosolum Diaiepami Compositae or Flvalscop)
Number of subjects: 120
Study 8156957 — intervention group
Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 120
Study 3351689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3351689 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16
Study 3351689 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 16
Study 3351689 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline plus diuretics
Number of subjects: 16
Study 28929443 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 hours fasting
Number of subjects: 9
Study 28929443 — intervention group
Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 9
Study 28929443 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and S-warfarin
Number of subjects: 9
Study 28448779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led care program (5 face-to-face educational sessions over 12 months)
Number of subjects: 152
Study 28448779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led care program
Number of subjects: 152
Study 28448779 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study 26209163 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic blockade of the posterior interosseous nerve (PIN)
Number of subjects: 80
Study 26209163 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential topical anesthetic blockade of skin surrounding the wrist
Number of subjects: 80
Study 26209163 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention with saline injection or inert ultrasound gel (control)
Number of subjects: 80
Study 24938449 — intervention group
Group type: EXPERIMENTAL
Intervention: LBS plus doxazosin
Number of subjects: 360
Study 24938449 — intervention group
Group type: COMPARATOR
Intervention: LBS placebo plus doxazosin
Number of subjects: 360
Study 24938449 — intervention group
Group type: EXPERIMENTAL
Intervention: LBS plus doxazosin placebo
Number of subjects: 360
Study 22491250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy (n = 15)
Number of subjects: 29
Study 22491250 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 14)
Number of subjects: 29
Study 20426588 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect/closed sinus floor elevation method
Number of subjects: 31
Study 20426588 — intervention group
Group type: COMPARATOR
Intervention: Control group (intra‐individual control)
Number of subjects: 31
Study 18547178 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cross-linked hyaluronic acid (SCHA)
Number of subjects: 10
Study 18547178 — intervention group
Group type: COMPARATOR
Intervention: Double cross-linked hyaluronic acid (DCHA)
Number of subjects: 10
Study 16089271 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate‐electrolyte (CE6)
Number of subjects: 10
Study 16089271 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% carbohydrate‐electrolyte (CE8)
Number of subjects: 10
Study 16089271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 12634887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 0
Study 12634887 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 12634887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 0
Study 10635187 — intervention group
Group type: EXPERIMENTAL
Intervention: CNC-milled frameworks
Number of subjects: 20
Study 10635187 — intervention group
Group type: COMPARATOR
Intervention: Conventional cast frameworks
Number of subjects: 20
Study 8960447 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 101
Study 8960447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8960447 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible Ischaemia
Number of subjects: 101
Study 1311653 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 56
Study 1311653 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 56
Study 1311653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hormones (Angiotensin II and Noradrenaline)
Number of subjects: 56
Study 4028805 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 25
Study 4028805 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 25
Study 4028805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 4028805 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 25
Study 31284568 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program plus food education program (experimental group; n = 20)
Number of subjects: 36
Study 31284568 — intervention group
Group type: COMPARATOR
Intervention: Exercise program (control group; n = 16)
Number of subjects: 36
Study 30056355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyometrial vasopressin plus rectal misoprostol (30 min before procedure)
Number of subjects: 60
Study 30056355 — intervention group
Group type: COMPARATOR
Intervention: Intramyometrial vasopressin alone
Number of subjects: 60
Study 27806250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarette (4% THC)
Number of subjects: 18
Study 24700631 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training group (19 boys, 22 girls) training twice a week for 8 weeks
Number of subjects: 125
Study 24700631 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training group (21 boys, 24 girls) training twice a week for 8 weeks
Number of subjects: 125
Study 24700631 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 boys, 21 girls; no training program)
Number of subjects: 125
Study 22064608 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month training program
Number of subjects: 84
Study 22064608 — intervention group
Group type: COMPARATOR
Intervention: 3-month training program
Number of subjects: 84
Study 20409203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Mix
Number of subjects: 50
Study 20409203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex
Number of subjects: 50
Study 18828243 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM) systems as a supplement to standard self-monitoring of blood glucose (SMBG)
Number of subjects: 0
Study 18828243 — intervention group
Group type: COMPARATOR
Intervention: Standard self-monitoring of blood glucose (SMBG) alone
Number of subjects: 0
Study 18828243 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM) systems
Number of subjects: 0
Study 16202722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical biopsies taken at different quadrants (12 o'clock, 6 o'clock, 3 o'clock, 9 o'clock)
Number of subjects: 0
Study 16202722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervigrams demonstrating visible intraepithelial lesions and acetowhitening
Number of subjects: 0
Study 12683344 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 41
Study 12683344 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 41
Study 10078888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 62
Study 10078888 — intervention group
Group type: COMPARATOR
Intervention: T'ai Chi
Number of subjects: 62